Archives202520242023202220212020201920182017201620152014201320122011 November 28, 2019ImmuPharma and Avion Pharmaceuticals sign exclusive licence Read More September 30, 2019INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2019 Read More July 04, 2019TR1 – Notification of Major Interest – Lanstead Capital Investors Read More July 02, 2019TR1 – Notification of Major Shareholding Read More June 28, 20192019 Annual General Meeting – All resolutions passed Read More June 28, 2019Primary endpoint successfully met from the open label extension study evaluating safety and tolerability from the Pivotal Phase III trial of Lupuzor™ in patients with Systemic Lupus Erythematosus (“Lupus”) Read More June 26, 2019Subscription to raise £2.66 million Read More June 04, 2019Notice of AGM and posting of Report & Accounts Read More May 24, 2019FINAL RESULTS ANNOUNCEMENT for the twelve months ended 31 December 2018 Read More May 07, 2019Corporate Update Read More April 01, 2019Update on Nucant cancer programme Read More March 14, 2019IMM March 2019 Corporate Update Read More 1…1213141516…24
June 28, 2019Primary endpoint successfully met from the open label extension study evaluating safety and tolerability from the Pivotal Phase III trial of Lupuzor™ in patients with Systemic Lupus Erythematosus (“Lupus”) Read More
